At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Sumanta K. Pal, MD, of City of Hope Comprehensive Cancer Center, Duarte, CA, discusses the results of the international phase 2 Borealis-1™ trial, which evaluated the efficacy and safety of gemcitabine and cisplatin plus apatorsen, a novel antisense oligonucleotide that inhibits Hsp27 production, in patients with advanced bladder cancer.
Borealis-1™: Phase 2 trial of gemcitabine/cisplatin plus apatorsen in advanced bladder cancer
13th August 2015
Oncology
Please rate the quality of this content
We are sorry that this content was not interesting for you!
Let us improve this content!
Tell us how we can improve this content?